Rx
Dual GIP and GLP-1 receptor agonistOnce-weekly dosingSubcutaneous injectionProvider-directed dose titration
Prescription · Provider-reviewed

Tirzepatide Weekly Injection

A once-weekly subcutaneous injection of compounded tirzepatide, a dual GIP and GLP-1 receptor agonist, prescribed only if a licensed provider decides it is clinically appropriate for you.

Weekly subcutaneous injection · Active ingredient: compounded tirzepatide, a dual GIP/GLP-1 receptor agonist. Supplied as a subcutaneous injection prepared by a licensed compounding pharmacy. Your specific formulation and excipients are detailed on the materials that accompany your prescription.

From$269/mo

All in: provider, medication, labs, shipping, and care coaching included. Starts at $339/mo.

This is compounded tirzepatide prepared by a licensed compounding pharmacy; compounded drugs are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality, and this is not the brand-name FDA-approved products Mounjaro or Zepbound.

See if it’s right for you

A licensed provider decides if it’s appropriate. A consultation doesn’t guarantee a prescription.

FSA & HSA eligibleVisa, Mastercard, Apple Pay & Google Pay accepted
For adults ages 18 to 74 with a BMI of 27 or higher, or a BMI of 25 or higher with a weight-related health condition. A licensed provider decides whether it is clinically appropriate for you; eligibility to start does not guarantee a prescription.

More than a prescription

Care, not just a refill

  • Visits with a U.S.-licensed provider
  • Your compounded medication, if prescribed
  • Lab orders and review when clinically needed
  • Unlimited messaging with your care team
  • Free, discreet shipping
  • Pause or cancel anytime
  • Care coaching with a dedicated medical assistant, at no extra cost

How it works

What it is and how it works

The science

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1. Through these receptors it supports glucose-dependent insulin release, lowers glucagon, slows how quickly the stomach empties, and signals areas of the brain involved in appetite and fullness. Engaging both receptors is what distinguishes it from single GLP-1 medicines. These effects can reduce appetite and food intake. Individual results vary.

Dual GIP and GLP-1 receptor agonistOnce-weekly dosingSubcutaneous injectionProvider-directed dose titration

Taking it

Weekly subcutaneous injection

Inject under the skin (subcutaneously) once a week, on the same day each week, rotating between the abdomen, thigh, and upper arm. Providers typically begin at a low dose and step it up gradually over time to help limit gastrointestinal side effects. Follow the exact dose, schedule, and storage instructions that accompany your medication, and do not change your dose without talking to your provider.

Common side effects

Most side effects are mild and tend to ease as your body adjusts. This isn’t a complete list. Your provider reviews the full picture with you and what to watch for.

  • Nausea, particularly when starting or increasing the dose
  • Diarrhea and vomiting
  • Constipation
  • Abdominal pain and indigestion
  • Decreased appetite
  • Injection-site reactions
  • Fatigue or burping
  • Rarely: pancreatitis, gallbladder problems, or serious allergic reaction

Important safety information

Boxed warning

In rodent studies, tirzepatide caused thyroid C-cell tumors; it is not known whether tirzepatide causes such tumors, including medullary thyroid carcinoma (MTC), in humans. Do not use if you or a family member have had MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Watch for a neck mass, trouble swallowing, hoarseness, or shortness of breath.

Important Safety Information. This is compounded tirzepatide, a dual GIP/GLP-1 receptor agonist; compounded drugs are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality. It is not Mounjaro or Zepbound, which are separate FDA-approved products. Tirzepatide may cause serious side effects including pancreatitis (severe, persistent abdominal pain that may spread to the back, with or without vomiting), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, vision changes, severe allergic reactions including anaphylaxis and angioedema, and a possible increased risk of depression or thoughts of self-harm. Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite. Do not use if pregnant, planning pregnancy, or breastfeeding. Tirzepatide may reduce the effectiveness of oral birth control; discuss backup contraception with your provider. Tell your provider about all your medical conditions and medications. Seek emergency care for severe or persistent abdominal pain, signs of a serious allergic reaction, or symptoms of severe low blood sugar. A licensed provider decides whether this medication is clinically appropriate for you; a consultation does not guarantee a prescription. Individual results vary.

Tirzepatide Weekly Injection is available by prescription only and only where a licensed provider determines it’s clinically appropriate. This information is educational and not a substitute for advice from your provider. Individual results vary. If you experience a serious reaction, seek medical care; for emergencies call 911.

Questions

Tirzepatide Weekly Injection FAQ

Tirzepatide Weekly Injection

From $269/mo

See if it’s right